Rapid Micro Biosystems Inc (RPID) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Rapid Micro Biosystems Inc stock $0.43, price $0.64, that is 32.9% below the price, quality 41 out of 100. Rating: overvalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 7, 2026.
How to read this chart
60‑month range $0.6030 – $23.35 · fair‑value band $0.2800 – $0.5300 · the $0.6410 price screens above the $0.4300 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 7, 2026.
Follow Rapid Micro Biosystems in your weekly email
Every Wednesday you see whether Rapid Micro Biosystems is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Rapid Micro Biosystems, Inc., a life sciences technology company, provides products for the detection of microbial contamination in the manufacture of pharmaceutical, biologics, medical devices, and personal care products in the United States, Switzerland, Germany, Japan, and internationally.
Show moreShow less
The company offers Growth Direct platform, which includes growth direct system, proprietary consumables, lab information management system connection software, and customer support and validation services.
Its platform automates and modernizes the antiquated, manual microbial quality control (MQC), testing workflows for therapeutic modalities, such as biologics and cell and gene therapies, vaccines, and sterile injectables. The company also provides onsite technical training services.
Its solutions are used in environmental monitoring, water, bioburden, and sterility release testing applications. In addition, the company offers RMBNucleus Mold Alarm software; and Growth Direct LIMS connection software.
Rapid Micro Biosystems, Inc. was formerly known as Genomic Profiling Systems, Inc. and changed its name to Rapid Micro Biosystems, Inc. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts.
Stock analysis
Rapid Micro Biosystems Inc (RPID) currently trades at $0.6410, while our model-based Fair Value estimate is $0.4300, 33% below the price, so the stock looks overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the data coverage at low.
Scenario range: $0.2800 (bear) to $0.5300 (bull), the price of $0.6410 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 41/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Rapid Micro Biosystems Inc reported revenue of $33.6M in FY2025 versus $23.2M in FY2021, a compound +9.7%/yr. Reported net income was −$47.1M in FY2025.
Key figures
Market cap $30.1M Micro · P/S ratio 0.91 · EPS (TTM) $−1.11 · Net margin −146% · Return on equity −142% · Return on assets (EBIT) −41.3% (5-year average) · Operating margin −153% · Revenue (TTM) $35.2M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 12 out of 100 (medium confidence).
What moves the price
The share trades about 86% below its 52-week high and 3% above its 52-week low.
For context, the median of 10 Healthcare peers we cover trades at −15% fair-value upside, at −33%, RPID screens richer than that median.
Fair Value models
Bear$0.2800Fair Value $0.4300Bull$0.5300
Price $0.6410 · Downside -32.9%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
In the last 6 months, no officer or director bought or sold shares on the open market.
SaleSean M WirtjesCHIEF FINANCIAL OFFICER3× since Feb 9, 2026: 30,761 shares, avg. $3.99$122,731Mar 11, 2026
SaleJohn J. Addington WilsonCHIEF OPERATING OFFICER3× since Feb 9, 2026: 19,616 shares, avg. $4.08$80,091Mar 11, 2026
SaleRobert G. Spignesi Jr.PRESIDENT AND CEO, Director3× since Feb 9, 2026: 69,089 shares, avg. $3.93$271,287Mar 10, 2026
SaleLongitude Venture Partners II, L.P.10% owner49,000 shares at $3.88$190,120Feb 4, 2026
SaleLongitude Prime Partners, LLC10% owner108,739 shares at $4.36$473,735Feb 3, 2026
Plus 12 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.36/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+19.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+25.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+15.9%
Start year 2020 (pandemic)
Revenue growth 15 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.0%
’10
’11
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−190.0% (2020) → −141.1% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Compare Rapid Micro Biosystems Inc with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 320 stocks
Beats the industry median on 3/9 measures
Overall it trails its industry peers.
Valuation
Quality Score41 · Bottom 25%
Fair Value upside−32.9% · Below median
Profitability
Return on assets−63.0% · Bottom 25%
Net margin (12 months)−145.6% · Bottom 25%
Operating margin (12 months)−153.0% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY)10.9% · Above median
Balance sheet
Debt / equity0.57× · Highest 25%
Valuation Multiplesvs Medical Devices median · lower = cheaper
P/B0.91× · Cheapest 25%
P/S (12 months)0.86× · Cheapest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 6
FUTURE (revenue growth)55· sector 35
PAST (return on equity)0· sector 17
HEALTH (low debt)72· sector 98
DIVIDEND (yield)0· sector 34
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Rapid Micro Biosystems Inc (RPID) overvalued or undervalued?
As of Nov 7, 2026, our model estimates a fair value of $0.4300 versus a price of $0.6410, about 33% lower (overvalued).
What is the fair value of RPID?
Our model-based fair value for Rapid Micro Biosystems Inc is $0.4300 (as of Nov 7, 2026), built from audited fundamentals. The current price: $0.6410.
What is the quality score of RPID?
Rapid Micro Biosystems Inc has a Quality Score of 41/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Rapid Micro Biosystems Inc (RPID)?
Our model-based price target is the fair value of $0.4300 (as of Nov 7, 2026) from 1 valuation models. Cautious scenario $0.2800, optimistic scenario $0.5300. It is a calculation from audited fundamentals, not an analyst target.
What is the Rapid Micro Biosystems Inc stock forecast for 2026?
Our models put fair value at $0.4300, about 33% lower versus a price of $0.6410 (overvalued). Cautious scenario $0.2800, optimistic scenario $0.5300. The calculation is refreshed regularly with new filings.
What is the revenue of Rapid Micro Biosystems Inc (RPID)?
Rapid Micro Biosystems Inc reported trailing-twelve-month revenue of about $35.2M (latest available figure, as of Nov 7, 2026).
What is the intrinsic value of Rapid Micro Biosystems Inc (RPID)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Rapid Micro Biosystems Inc it is $0.4300 per share (as of Nov 7, 2026), against a price of $0.6410. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is Rapid Micro Biosystems Inc stock overvalued or undervalued in 2026?
As of Nov 7, 2026, RPID trades above its calculated fair value: price $0.6410, fair value $0.4300, a gap of about −33% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of RPID?
No. The price is what the market pays today ($0.6410); the fair value is what the company's own numbers justify ($0.4300). For Rapid Micro Biosystems Inc the two are $0.2110 per share apart. That gap is exactly why we show both numbers side by side.
How much is Rapid Micro Biosystems Inc worth?
The market values Rapid Micro Biosystems Inc at about $30.1M (market capitalisation, as of Nov 7, 2026). Per share that is $0.6410; our models calculate a fair value of $0.4300 per share.
What do the bullish and bearish scenarios say about RPID?
Our models span a range for Rapid Micro Biosystems Inc: cautious scenario $0.2800, base $0.4300, optimistic $0.5300 per share (as of Nov 7, 2026, price $0.6410). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Rapid Micro Biosystems Inc (RPID)?
Balance-sheet figures for Rapid Micro Biosystems Inc (as of Nov 7, 2026): return on equity −141.7%, debt of 0.57 per unit of equity. They feed the Quality Score of 41/100, which measures business quality independently of the share price.
How far is RPID from its 52-week high?
Rapid Micro Biosystems Inc trades at $0.6410, about 86% below its 52-week high of $4.68 and 3% above the low of $0.6200 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $0.4300 is for.
Which stocks are comparable to Rapid Micro Biosystems Inc?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Rapid Micro Biosystems Inc stock attractive at the current price?
The data as of Nov 7, 2026: price $0.6410, calculated fair value $0.4300 (−33%), Quality Score 41/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of RPID calculated?
We run Rapid Micro Biosystems Inc through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of $0.4300 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0% above its aggregate fair value. Rapid Micro Biosystems Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Rapid Micro Biosystems Inc (RPID)?
The closing price on Nov 6, 2026 was $0.6410. Our model-based fair value is $0.4300, about 33% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Rapid Micro Biosystems Inc right now?
The price sits above even our optimistic bull case ($0.5300). The favourable scenario is already priced in. Weak quality (41/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range ($0.2800 to $0.5300) leaves room in how you read the outcome.
Key figures of Rapid Micro Biosystems Inc
How large is the market capitalisation of Rapid Micro Biosystems Inc (RPID)?
The market capitalisation of Rapid Micro Biosystems Inc is $30.1M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Rapid Micro Biosystems Inc (RPID)?
The price-to-sales ratio of Rapid Micro Biosystems Inc is 0.91 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Rapid Micro Biosystems Inc (RPID)?
Earnings per share at Rapid Micro Biosystems Inc are $−1.11. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Rapid Micro Biosystems Inc (RPID)?
The net margin of Rapid Micro Biosystems Inc is −146% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Rapid Micro Biosystems Inc (RPID)?
The return on equity (ROE) of Rapid Micro Biosystems Inc is −142% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Rapid Micro Biosystems Inc (RPID)?
On an EBIT basis the return on assets of Rapid Micro Biosystems Inc is −41.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Rapid Micro Biosystems Inc (RPID)?
The operating margin of Rapid Micro Biosystems Inc is −153% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Rapid Micro Biosystems Inc (RPID)?
Revenue at Rapid Micro Biosystems Inc is growing +10.9% versus a year earlier (3y avg +25.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Rapid Micro Biosystems Inc (RPID) generate?
The free cash flow of Rapid Micro Biosystems Inc is −$31.9M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Rapid Micro Biosystems Inc (RPID) carry?
The net debt of Rapid Micro Biosystems Inc is $3.8M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Rapid Micro Biosystems Inc in the live analysis
One click puts Rapid Micro Biosystems Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 7, 2026
